REVELATION BIOSCIENCES INC (REVB)
US76135L5075 - Common Stock
Taking everything into account, REVB scores 1 out of 10 in our fundamental rating. REVB was compared to 568 industry peers in the Biotechnology industry. The financial health of REVB is average, but there are quite some concerns on its profitability. REVB does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year REVB has reported negative net income.
In the past year REVB has reported a negative cash flow from operations.
REVB had negative earnings in each of the past 5 years.
REVB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
REVB has a Return On Assets of -230.20%. This is amonst the worse of the industry: REVB underperforms 91.86% of its industry peers.
REVB's Return On Equity of -580.33% is on the low side compared to the rest of the industry. REVB is outperformed by 80.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -230.2% | ||
| ROE | -580.33% | ||
| ROIC | N/A |
ROA(3y)-261.6%
ROA(5y)-171.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
REVB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, REVB has more shares outstanding
There is no outstanding debt for REVB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
REVB has an Altman-Z score of -11.50. This is a bad value and indicates that REVB is not financially healthy and even has some risk of bankruptcy.
REVB's Altman-Z score of -11.50 is on the low side compared to the rest of the industry. REVB is outperformed by 76.99% of its industry peers.
There is no outstanding debt for REVB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.5 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 1.64 indicates that REVB should not have too much problems paying its short term obligations.
REVB has a worse Current ratio (1.64) than 80.71% of its industry peers.
REVB has a Quick Ratio of 1.64. This is a normal value and indicates that REVB is financially healthy and should not expect problems in meeting its short term obligations.
REVB's Quick ratio of 1.64 is on the low side compared to the rest of the industry. REVB is outperformed by 79.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.64 | ||
| Quick Ratio | 1.64 |
3. Growth
3.1 Past
The earnings per share for REVB have decreased strongly by -259.62% in the last year.
EPS 1Y (TTM)-259.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to decrease by -56.96% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-113.8%
EPS Next 2Y-42.8%
EPS Next 3Y-26.38%
EPS Next 5Y-56.96%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for REVB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for REVB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
REVB's earnings are expected to decrease with -26.38% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-42.8%
EPS Next 3Y-26.38%
5. Dividend
5.1 Amount
No dividends for REVB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REVELATION BIOSCIENCES INC
NASDAQ:REVB (12/20/2024, 8:00:01 PM)
After market: 0.3005 +0.01 (+1.86%)0.295
-0.02 (-6.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.35%
Inst Owner Change130%
Ins Owners0.08%
Ins Owner Change0%
Market Cap1.91M
Analysts82.86
Price Target13.01 (4310.17%)
Short Float %2.93%
Short Ratio0.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-53.82%
Min EPS beat(2)-178.64%
Max EPS beat(2)71%
EPS beat(4)3
Avg EPS beat(4)-2.93%
Min EPS beat(4)-178.64%
Max EPS beat(4)71%
EPS beat(8)6
Avg EPS beat(8)63.92%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.76%
PT rev (3m)-24.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)55.19%
EPS NY rev (1m)34.27%
EPS NY rev (3m)39.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.71 | ||
| P/tB | 0.71 | ||
| EV/EBITDA | N/A |
EPS(TTM)-16.76
EYN/A
EPS(NY)-2.17
Fwd EYN/A
FCF(TTM)-2.57
FCFYN/A
OCF(TTM)-2.57
OCFYN/A
SpS0
BVpS0.41
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -230.2% | ||
| ROE | -580.33% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-261.6%
ROA(5y)-171.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.64 | ||
| Quick Ratio | 1.64 | ||
| Altman-Z | -11.5 |
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-259.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.33%
EPS Next Y-113.8%
EPS Next 2Y-42.8%
EPS Next 3Y-26.38%
EPS Next 5Y-56.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-13.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-26.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.05%
OCF growth 3YN/A
OCF growth 5YN/A